On May 26, 2026 Akeso, Inc. (9926.HK) ("Akeso" or the "Company") reported that more than 40 clinical studies of its oncology portfolio will be presented at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, taking place May 29 – June 2 in Chicago, Illinois. Notably, the presentations include one Late-Breaking Abstract (LBA) selected for the prestigious Plenary Session, alongside four Oral or Rapid Oral presentations.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The datasets featured at ASCO (Free ASCO Whitepaper) 2026 primarily highlight the Company’s core first-in-class bispecific antibodies — cadonilimab (PD-1/CTLA-4) and ivonescimab (PD-1/VEGF) — along with other novel therapeutic antibodies such as ligufalimab, a next-generation CD47 monoclonal antibody. These presentations include several potentially practice-changing datasets across multiple tumor types.
A pivotal highlight will be the Phase III overall survival (OS) results from the HARMONi-6 study, evaluating the survival advantage of ivonescimab combined with chemotherapy versus a PD-1 inhibitor combined with chemotherapy in the first-line setting for advanced squamous non-small cell lung cancer (sq-NSCLC). Additional notable presentations feature ivonescimab in small-cell lung cancer (SCLC) that has progressed after first-line chemoimmunotherapy, ivonescimab plus chemotherapy in first-line metastatic colorectal cancer (mCRC) from a global Phase II interim analysis, alongside cadonilimab-based regimens in renal cell carcinoma, melanoma, colorectal cancer, head and neck cancer, gynecologic malignancies, and biliary tract cancer.
The maturity and breadth of these datasets underscore the success of Akeso’s innovation engine, demonstrating the clinical benefits of the Company’s differentiated bispecific antibody platform to the international oncology community.
Key Presentations
Plenary Session
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in previously untreated advanced squamous non-small cell lung cancer: Overall survival results of the Phase 3 HARMONi-6 study
Abstract: LBA4
Session: Plenary Session
Date/Time (CDT): May 31, 2026, 2:47 PM–2:59 PM
Presenter: Professor Shun Lu, Shanghai Chest Hospital
Oral Presentation
Efficacy and safety of ivonescimab combined with liposomal irinotecan in patients with small-cell lung cancer (SCLC) progressing after first-line chemoimmunotherapy: A multicenter, Phase 2 study
Abstract: 8007
Date: June 2, 2026
Presenter: Professor Yun Fan, Zhejiang Cancer Hospital
Oral Presentation
A prospective, multicenter, Phase Ib/II trial of first-line cadonilimab plus axitinib in advanced non–clear cell renal cell carcinoma
Abstract: 4501
Date: June 2, 2026
Presenter: Dr. Junru Chen, West China Hospital, Sichuan University
Rapid Oral Presentation
Neoadjuvant ivonescimab (AK112, a PD-1/VEGF bispecific antibody) combined with nab-paclitaxel and cisplatin for resectable locally advanced head and neck squamous cell carcinoma (LA-HNSCC): An exploratory Phase II study
Abstract: 6014
Date: June 2, 2026
Presenter: Professor Kunyu Yang, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Rapid Oral Presentation
Cadonilimab or ivonescimab plus axitinib in metastatic mucosal melanoma: Results from a Phase Ib trial
Abstract: 9516
Date: May 31, 2026
Presenter: Professor Lili Mao, Peking University Cancer Hospital
International Multicenter Phase II Study
Ivonescimab (ivo) with oxaliplatin + fluorouracil (5-FU) + leucovorin calcium (mFOLFOX6) for patients (pts) with unresectable metastatic colorectal cancer (mCRC): A phase II study
Abstract: 3576
Date: May 30, 2026
First Author: David Berz, MD, PhD, Department of Oncology, Valkyrie Clinical Trials, Inc
(Press release, Akeso Biopharma, MAY 26, 2026, View Source [SID1234666069])